CoChat

Monitoring Allergen Immunotherapy Effects by Microarray

Open access
Lupinek, Christian, Wollmann, Eva, Valenta, Rudolf · 2016 · Current Treatment Options in Allergy
Cited by 36

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

During the last decades, the prevalence of IgE-associated allergies increased worldwide, affecting currently millions of patients, some of whom suffering from severe or even life-threatening conditions [ 1 – 7 ]. Analysis of approximately 6500 sera from population-based European birth cohorts in the course of the MeDALL project [ 8 ] indicates an even higher percentage of sensitized children which most probably will lead to higher prevalence of allergic disease in the decades to come. Symptomatic medications like antihistamines, mast cell stabilizing agents, leukotriene receptor antagonists or, in more severe cases, corticosteroids or anti-IgE antibodies only have short-term effects and need to be administered regularly which causes considerable costs and burden to the patients due to adverse effects of the drugs. Allergen immunotherapy (AIT) is a cost-effective therapy and, so far, the only treatment that can yield sustained symptomatic improvement [ 9 ]. However, there are several factors that may hamper clinical efficacy of AIT, some of which are directly associated with the use of allergen extracts for vaccination. Due to the great variability of natural allergen sources regarding allergen composition and concentration, allergen extracts used both for diagnosis and therapy show considerable variation when products from different producers or different batches are compared [ 10 – 14 ]. In addition, specimens from particular allergen sources may contain clinically relevant allergens but their amounts are insufficient, e.g., Der p 23 from house dust mite [ 15 ], or are in general difficult to extract, like material from fungi [ 16 , 17 ]. Therefore, vaccines for AIT that are based on natural allergen extracts often do not cover the individual sensitization profile of the patient in terms of allergen composition and thus, treatment may fail in such cases. However, even if the vaccine does contain all clinically relevant allergen molecules it is not possible to predict for the individual patient if AIT is likely to induce a beneficial immune response because certain allergens may exhibit low immunogenicity and/or there may be non-responders among patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40521-016-0084-2

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 36

Metadata

Authors
Lupinek, C., Wollmann, E., & Valenta, R.
Venue
Current Treatment Options in Allergy
Published
2016-04-20
Volume
3
Issue
2
Pages
189-203
ISSN
2196-3053 (ISSN-L)
OpenAlex
W2338799715
Cited by
36
References
8
FWCI
4.44
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Monitoring Allergen Immunotherapy Effects by Microarray. https://app.cochat.ai/papers/10.1007/s40521-016-0084-2
The paper
Lupinek, C., Wollmann, E., & Valenta, R. (2016). Monitoring Allergen Immunotherapy Effects by Microarray. Current Treatment Options in Allergy. https://doi.org/10.1007/s40521-016-0084-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.